DISEASE IMPACT AND COST-EFFECTIVENESS OF A NEW DENGUE VACCINE TAK003 IN THAILAND
Intro: Dengue, a vector-borne disease, is a global threat to public health with incidence increased from 0.5 to 5.2 million cases between 2010 and 2019. Data collected over ∼57 months of the phase-3 DEN-301 trial of the candidate vaccine (TAK-003) demonstrated long-term efficacy against symptomatic...
Main Authors: | J. Shen, E. Kharitonova, S. Biswal, M. Sharma, S. Aballea, A. Tytuła, J. Zawieja, P. Towle, R. Hanley |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-05-01
|
Series: | International Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223004769 |
Similar Items
-
Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
by: Inge LeFevre, et al.
Published: (2023-05-01) -
Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV, TDV (TAK-003), and TV003/TV005
by: Yoseph Jeffry Hertanto, et al.
Published: (2021-12-01) -
GRADE 3 SOLICITED AND UNSOLICITED ADVERSE EVENTS (AES) FOLLOWING VACCINATION WITH TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003)
by: E. Ismail, et al.
Published: (2023-05-01) -
EFFICACY AND SAFETY OF TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) AFTER 4.5 YEARS OF FOLLOW-UP: RESULTS FROM PARTICIPANTS IN ASIA
by: A. Green, et al.
Published: (2023-05-01) -
BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS
by: C. Halim, et al.
Published: (2023-05-01)